2022
DOI: 10.1007/978-3-030-91836-1_16
|View full text |Cite
|
Sign up to set email alerts
|

Multi-Omics Profiling of the Tumor Microenvironment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(6 citation statements)
references
References 305 publications
0
6
0
Order By: Relevance
“…TME composition affects immune cells’ ability to locate and kill malignant cells, the bioavailability and effectiveness of chemotherapy drugs, the availability of oxygen and other nutrients needed for cancer cell growth, and the possibility of metastasis [2, 3]. For these reasons, thorough characterization of the TME is an active area of cancer research [4, 5].…”
Section: Introductionmentioning
confidence: 99%
“…TME composition affects immune cells’ ability to locate and kill malignant cells, the bioavailability and effectiveness of chemotherapy drugs, the availability of oxygen and other nutrients needed for cancer cell growth, and the possibility of metastasis [2, 3]. For these reasons, thorough characterization of the TME is an active area of cancer research [4, 5].…”
Section: Introductionmentioning
confidence: 99%
“…( a ) UMAP plot showing the breast cancer atlas based on two previously published single-cell RNA-seq datasets. 21,23 ( b ) Verification of the cellular annotation of the newly generated breast cancer atlas using several cell-specific genes. ( c ) Deconvolution of two cell populations in the spatial single-cell RNA-seq data using the breast cancer cell atlas (left panels) and confirmation of the deconvolution by histology analysis (right panel).…”
Section: Resultsmentioning
confidence: 99%
“…We also analyzed the tumor genomic heterogeneity of SERPINA1 mutations in pan-cancer [39], and a growing number of studies have found that other tumor heterogeneity analyses are also emerging clinical biomarkers in immunotherapy, clinical outcomes, and chemotherapy [55,56]. In addition, tumor heterogeneity based on SERPINA1 mutations in pan-cancer was also observed.…”
Section: Discussionmentioning
confidence: 99%